阿德福韦酯联合胸腺肽α1治疗拉米夫定无应答的HBeAg阳性慢性乙肝的疗效观察

Clinical effect of adefovir dipivoxil combined with thymosin α in the treatment of paitents with HBeAg positive and no response to lamivudine

目的探讨拉米夫定无应答HBeAg阳性慢性乙肝病人进行胸腺肽α1与阿德福韦酯联合疗法的临床效果。方法将拉米夫定无应答HbeAg阳性乙型慢性肝炎病人80例，按照随机数字表法分为研究组和对照组，各组40例。研究组进行胸腺肽α1与阿德福韦酯联合疗法，对照组仅进行胸腺肽α1治疗，治疗期为半年。比较两组治疗前后的谷丙转氨酶（ALT）、谷草转氨酶（AST）、γ-转肽酶（γ—GT）水平；比较两组治疗前后的HBeAg／抗-HBe转换、HBVDNA阴转情况。结果治疗后两组的ALT、AST、γ-GT水平均有改善，但研究组治疗后的ALT、AST、γ—GT水平显著优于对照组，差异有统计学意义（P〈0．05）；研究组治疗后的HBeAg／抗-HBe转换、HBVDNA阴转情况显著优于对照组，差异有统计学意义（P〈0．05）。结论拉米夫定无应答的HBeAg阳性慢性乙型肝炎病人进行胸腺肽d1与阿德福韦酯联合疗法，可显著改善病人的肝功能状态，临床效果确切，值得临床推广。

Objective To Analysis analysis the clinical effects of the combined therapty of adefovir dipivoxil combined and thymosin α1 in the treatment of chronic hepatitis patients with HBeAg positive and no response to lamivudineamivudine. Methods Eighty chronic hepatitis patients with HBeAg positive and no response to lamivudine were selected as the research objects and were divided into the research group and the control group according to the random number table. The research group was treated by adefovir dipivoxil combined with thymosin α1 and control group was treated with thymosin α1. Treatment period was half of a year. Alanine aminotransferase （ALT）, aspartate aminotransferase （AST）, gamma turn peptidase （γ-GT） were compared between the two groups. HBeAg/anti-HBe seral conversion and HBV DNA negative conversion were compared between the two groups. Results The level of ALT, AST and γ-GT of research group were superior to that of the control group （P 〈 0.05）. The data of HBeAg/anti-HBe conversion and HBV DNA negative conversion were were superior to that of the control group （ P 〈 0. 05）. Conclusions The therapeuty of adefovir dipivoxil combined with thymosin α1 can significantly improve the patient＇s liver function, and is worth of being promted in clinical practice.